Tripos Announces Partnership With Pfizer

Software License Covers Worldwide Access to Tripos' Discovery Technologies

04-Jan-2002

ST. LOUIS, MO - January 3, 2002 - Tripos, Inc. a provider of drug discovery chemistry, software and services, today announced a multi-million dollar, multi-year agreement with Pfizer Global Research and Development to license its suite of discovery software technologies, including the industry-leading SYBYL® and UNITY® programs, to Pfizer research locations worldwide. Tripos' discovery software will be used by Pfizer research scientists to manage, analyze and share biological and chemical information. Further terms of the agreement were undisclosed.

Tripos' leading-edge computational tools help researchers extract usable information from the volumes of data generated by the high-throughput technologies that characterize modern research methods. The Company's virtual combinatorial chemistry technologies cover a wide variety of scientific applications and enable scientists to work in silico to reach knowledge-driven research decisions, avoiding the costly synthesis and testing of chemical compounds that are not likely to be effective.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances